- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02448810
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Florida
-
Port Saint Lucie, Florida, United States, 34952
- Hematology Oncology Associates of the Treasure Coast
-
-
Illinois
-
Joliet, Illinois, United States, 60435
- Joliet Oncology-Hematology Associates, Ltd.
-
-
Indiana
-
Goshen, Indiana, United States, 46526
- Indiana University Health
-
-
Maryland
-
Rockville, Maryland, United States, 20850
- Maryland Oncology Hematology, P.A.
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
New York
-
Bronx, New York, United States, 10461
- Montefiore Einstein Center for Cancer Care
-
New York, New York, United States, 10003
- Mount Sinai Beth Israel
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma Health Sciences Center
-
-
South Carolina
-
Charleston, South Carolina, United States, 29412
- Medical University of South Carolina (MUSC)
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- The Jones Clinic, PC
-
-
Texas
-
Dallas, Texas, United States, 75230
- Mary Crowley Cancer Research Center
-
San Antonio, Texas, United States, 78229
- CTRC at University of Texas Health Science Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of a signed informed consent
- Male and female subjects 18 years of age and older at the time of screening
- Subjects who progressed after receiving at least 2, but no more than 3, prior SoC treatment lines
- Anticipated life expectancy >3 months at the time of screening
- Weight between 40 kg and 180 kg
- Histologically or cytologically confirmed diagnosis of CRC
- Metastatic CRC not amenable to surgical resection
- Known KRAS and NRAS mutation status (if unknown status for either of these genes, and no archival tissues is available, a fresh tumor biopsy will be made)
- At least 1 measurable lesion as defined by RECIST v1.1
- ECOG PS of 0-2
Adequate hematological function, defined as:
- Platelet count ≥ 100,000/μL
- Prothrombin time and activated partial thromboplastin time (aPTT) < 1.5 times the upper limit of normal (ULN)
- Absolute neutrophil count (ANC) ≥ 1,000/μL
- Hemoglobin ≥ 9 g/dL, without the need for transfusion in the 2 weeks prior to screening
- Adequate renal function, defined as serum creatinine ≤ 2.0 times ULN and creatinine clearance > 50 mL/min
Adequate liver function, defined as:
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
≤ 2.5 times ULN for subjects without liver metastases, or ≤ 5 times ULN in the presence of liver metastases
- Bilirubin ≤ 2.0 times ULN, unless subject has known Gilbert's syndrome
- Adequate venous access
- For female subjects of childbearing potential, the subject presents with a negative serum pregnancy test at screening and agrees to employ 2 forms of adequate birth control measures, including at least 1 barrier method (eg, diaphragm with spermicidal jelly or foam, or [for male partner] condom) throughout the course of the study and for at least 90 days after the last administration of BAX69. Other acceptable contraceptive measures include birth control pills/patches or intrauterine devices
- For male subjects, the subject must agree to use adequate contraceptive measures including at least 1 barrier method (eg, condom with spermicidal jelly or foam and [for the female partner] diaphragm with spermicidal jelly or foam, birth control pills/patches, or intrauterine device) and abstain from sperm donation throughout the course of the study and for at least 90 days after the last administration of BAX69
- Subject is willing and able to comply with the requirements of the protocol.
Exclusion Criteria:
- Known central nervous system metastases
- Prior malignancy(s) within the past 3 years, with the exception of curatively treated basal or squamous cell carcinoma of the skin, locally advanced prostate cancer, ductal carcinoma in situ of breast, in situ cervical carcinoma and superficial bladder cancer
- Prior treatment with panitumumab for subjects with KRAS and NRAS wt tumor
- Residual AE from previous treatment > Grade 1
- Prior intolerance to fluoropyrimidine for subjects with KRAS or NRAS mut tumor
- Myocardial infarction within 6 months prior to C1D1, and/or prior diagnoses of congestive heart failure (New York Heart Association Class III or IV), unstable angina, unstable cardiac arrhythmia requiring medication; and/or the subject is at risk for polymorphic ventricular tachycardia (eg, hypokalemia, family history or long QT syndrome)
- Uncontrolled hypertension defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg confirmed upon repeated measures
- LVEF < 40% as determined by echocardiogram performed at screening or within 90 days prior to C1D1
- QT/QTc interval > 450 msec, as determined by screening ECG performed no earlier than 1 week before C1D1
- Prior anti-tumor therapy (chemotherapy, radiotherapy, antibody therapy, molecular targeted therapy, retinoid therapy or hormonal therapy) within 4 weeks prior to C1D1.
- Major surgery within 4 weeks prior to C1D1
- Active joint inflammation or history of inflammatory arthritis or other immune disorder involving joints
- Active infection involving IV antibiotics within 2 weeks prior to C1D1
- Known history of, or active hepatitis B virus (HBV), hepatitis C virus (HCV) or active tuberculosis
- Known history of human immunodeficiency virus (HIV) type 1/2 or other immunodeficiency disease
- Subject has received a live vaccine within 4 weeks prior to C1D1
- Known hypersensitivity to any component of recombinant protein production by CHO cells
- Exposure to an investigational product or investigational device in another clinical study within 4 weeks prior to C1D1, or is scheduled to participate in another clinical study involving an investigational product or device during the course of this study
- Subject is nursing or intends to begin nursing during the course of the study
- Any disorder or disease, or clinically significant abnormality on laboratory or other clinical test(s) (eg, blood tests, ECG), that in medical judgment of the investigator may impede the subject's participation in the study, pose increased risk to the subject, and/or confound the results of the study
- Subject is a family member or employee of the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1: Subjects with mutated tumor (mt) (KRAS or NRAS)
Subjects stratified according to their mutation status.
|
Study Part 1: Safety Run-in
Other Names:
|
Experimental: Part 1: Subjects with wild-type (wt) tumor (KRAS and NRAS wt)
Subjects stratified according to their mutation status.
|
Study Part 1: Safety Run-in
Other Names:
Study Part 2: Administered weekly as part of a 4 week treatment cycle •Intravenous injection
Other Names:
|
Experimental: Part 2: Subjects with KRAS or NRAS mutated
Subjects stratified according to their mutation status.
|
Study Part 2: Administered weekly as part of a 4 week treatment cycle •Intravenous injection
Other Names:
|
Experimental: Part 2: Subjects with KRAS and NRAS wt tumor
Subjects stratified according to their mutation status.
|
Study Part 1: Safety Run-in
Other Names:
Study Part 2: Administered weekly as part of a 4 week treatment cycle •Intravenous injection
Other Names:
|
Active Comparator: Part 2: Standard of Care- Subjects with KRAS or NRAS mutated
Subjects stratified according to their mutation status.
|
|
Active Comparator: Part 2: Standard of Care- Subjects with KRAS and NRAS wt tumor
Subjects stratified according to their mutation status.Subjects stratified according to their mutation status.
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 2: Progression-Free Survival (PFS)
Time Frame: From start of the study up to safety follow-up visit occurred (30 [-/+7]) days after the last dose of study treatment or until disease progression
|
PFS was defined as time between treatment initiation and tumor progression (per Response Evaluation Criteria in Solid Tumors [RECIST] v1.1 criteria) or death from any cause, with censoring of participants who were lost to follow-up or withdrew consent.
|
From start of the study up to safety follow-up visit occurred (30 [-/+7]) days after the last dose of study treatment or until disease progression
|
Part 1: Number of Participants With Occurrence of Dose Limiting Toxicity (DLT)
Time Frame: From start of study treatment up to 28 days
|
DLT was defined as any drug-related treatment-emergent adverse event (TEAE) (graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v4.03) that occurs during the first 28 days after treatment start and that meets any of the following criteria: i) Any >= Grade 3 non-hematologic toxicity (excluding: mucositis/stomatitis of Grade 3; diarrhea of <3 days duration; nausea and vomiting <3 days duration; fatigue of <7 days duration; alopecia; single laboratory value out of the normal range that has no clinical significance and that resolves to <= Grade 2 with adequate measures within 7 days) ii) Any Grade 4 hematologic toxicity (excluding: grade 4 neutropenia lasting for <= 5 days; isolated grade 4 lymphocytopenia) iii) Grade 3 febrile neutropenia iv) Grade 3 thrombocytopenia associated with bleeding v) Any life-threatening complication or abnormality not covered in NCI CTCAEv4.03.
|
From start of study treatment up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Occurrence of Binding and/or Neutralizing Anti-imalumab Antibodies
Time Frame: From start of study drug administration up to end of treatment (EOT) (approximately 21 Months)
|
Number of participants with occurrence of binding and/or neutralizing anti-imalumab antibodies were reported.
|
From start of study drug administration up to end of treatment (EOT) (approximately 21 Months)
|
Number of Participants With Incidence of Infusion Reactions After Imalumab Administration
Time Frame: From start of study drug administration up to EOT (approximately 21 Months)
|
Infusion reaction was defined as any relevant sign or symptom occurring during or after imalumab infusion and considered by the investigator as an infusion reaction.
|
From start of study drug administration up to EOT (approximately 21 Months)
|
Number of Participants With Serious Adverse Events (SAEs) and Treatment-emergent Adverse Events (TEAEs)
Time Frame: From start of study drug administration up to EOT (approximately 21 Months)
|
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
SAE was any AE that results in any of the following outcomes: death, a life-threatening event, inpatient hospitalization or prolongation of an existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly/birth defect, other medically important events based upon appropriate medical judgement.
TEAEs was defined as any event not present prior to the initiation of the treatments or any event already present that worsens in either intensity or frequency following exposure to the treatments.
|
From start of study drug administration up to EOT (approximately 21 Months)
|
Number of Participants With Response Evaluation According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Time Frame: Day 28 of Cycle 2 followed by every 2 Cycles of 28 day Cycles: Day 56, Day 112, Day 168 and Day 224
|
Number of participants with response evaluation according to RECIST v1.1 was evaluated according to complete response (CR): disappearance of all target and non-target lesions and no new lesions; partial response (PR): >= 30 percent (%) decrease in the sum of diameters of target lesions (compared to baseline) and no new lesions; stable disease (SD): neither sufficient shrinkage to qualify as a response nor sufficient growth to qualify as progression; progressive disease (PD): >= 20% increase in the sum of diameters of target lesions and an absolute increase in sum of diameters of >=5 millimeter (mm) (compared to the previous minimum sum) or progression of a new lesion.
|
Day 28 of Cycle 2 followed by every 2 Cycles of 28 day Cycles: Day 56, Day 112, Day 168 and Day 224
|
Overall Survival
Time Frame: From start of study drug administration up to EOT (approximately 21 Months)
|
Overall survival was defined as the time from randomization until death due to any cause.
Here, number of participants analyzed was based on the number of participants who underwent death.
|
From start of study drug administration up to EOT (approximately 21 Months)
|
Change From Baseline for Quality of Life (QoL) Measure - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Time Frame: Baseline, 21 Months (EOT) up to follow-up
|
EORTC QLQ-C30 was a validated instrument used to measure QoL and assess symptoms and side effects of treatment and the impact on everyday life.The QLQ-C30 was composed of: A) 5 multi-item functioning scales(physical, role, social, emotional and cognitive), that were answered on a 4-point scale (1=Not at all,2=A Little,3=Quite a Bit,4=Very Much).
Each score range from 0 to 100 with a higher score representing a higher level of functioning and a better QoL.
B) A global health status/QoL scale that was answered on a 7-point scale (1=Very Poor to 7=Excellent).
Each score range from 0 to 100 with a higher score representing a better QoL.
C) 9 symptom scales(fatigue, nausea/vomiting,pain,financial impact/difficulties,appetite loss,diarrhea, constipation,sleep disturbance/insomnia and dyspnea), that were answered on a 4-point scale (1=Not at all,2=A Little,3=Quite a Bit,4=Very Much).
Each score range from 0 to 100 with a higher score representing a greater degree of symptoms and a worse QoL.
|
Baseline, 21 Months (EOT) up to follow-up
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Fluorouracil
- Panitumumab
Other Study ID Numbers
- 391401
- 2015-000896-28 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Lung | Resectable Colorectal CarcinomaUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
Clinical Trials on BAX69 + infusional 5-FU/LV
-
Ralf HofheinzInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Deutsche... and other collaboratorsRecruiting
-
PfizerCompletedColorectal NeoplasmsAustralia, Canada, United States, New Zealand
-
Taian Cancer HospitalUnknownEsophageal CarcinomaChina
-
Fundación de investigación HMSyntax for Science, S.LCompletedLocally Advanced Rectal Cancer (LARC)Spain
-
Uppsala UniversityCompletedGastric Cancer | Peritoneal CarcinomatosisSweden
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaCompleted
-
Eastern Hepatobiliary Surgery HospitalNot yet recruitingHepatocellular CarcinomaChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
CSPC Ouyi Pharmaceutical Co., Ltd.UnknownAdvanced Pancreatic CancerChina